# US 2016/0355783 A1 · Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355783 A1
- Document ID: US20160355783A1
- Status: Published application
- Kind: A1
- Application number: 15/178,715
- Filed: 2016-06-10
- Published: 2016-12-08
- Earliest claimed: 2011-12-22
- Assignees: Elwha LLC
- Applicants: Elwha LLC
- Inventors: Roderick A. Hyde; Wayne R. Kindsvogel
- Web page: https://patentgrep.com/patent/US20160355783A1

## CPC

- C12N 5/0635: {B lymphocytes}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 40/13: B-cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4274: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]}
- A61K 40/4275: {Prostate specific antigen [PSA]}
- A61K 40/4532: {Staphylococcus}
- A61K 40/46: Viral antigens
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C07K 16/118: Hepatitis C virus; GB virus C [GBV-C]
- C07K 16/1271: Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
- C07K 16/18: against material from animals or humans
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C12N 15/85: for animal cells
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/58: Prostate
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.

## Claims

### Claim 1

An isolated cell line comprising:
an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin or a recombinant B cell receptor that is reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen;
wherein the isolated B lymphocyte cell line is capable of expressing cytotoxicity for at least one target cell.

### Claim 2 (depends on 1)

The isolated cell line of claim 1, further including the isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to the second antigen.

### Claim 3 (depends on 1)

The isolated cell line of claim 1, wherein the at least one exogenously incorporated membrane immunoglobulin includes one or more exogenously incorporated membrane immunoglobulin polypeptides.

### Claim 4 (depends on 1)

The isolated cell line of claim 1, wherein the at least one exogenously incorporated membrane immunoglobulin includes at least one exogenously incorporated nucleic acid encoding the at least one membrane immunoglobulin, wherein the cell line is capable of expressing the at least one membrane immunoglobulin.

### Claim 5 (depends on 1)

The isolated cell line of claim 1, wherein the at least one exogenously incorporated membrane immunoglobulin includes at least two exogenously incorporated nucleic acids encoding the at least one membrane immunoglobulin.

### Claim at position 6

-10. (canceled)

### Claim 11 (depends on 1)

The isolated cell line of claim 1, wherein the isolated B lymphocyte cell line is capable of disrupting expression of the endogenous membrane immunoglobulin reactive to the second antigen.

### Claim at position 8

-14. (canceled)

### Claim 15 (depends on 1)

The isolated cell line of claim 1, wherein the at least one exogenously incorporated membrane immunoglobulin activated by the first antigen is capable of controlling expression of the at least one endogenous secreted immunoglobulin reactive to the second antigen.

### Claim 16 (depends on 1)

The isolated cell line of claim 1, wherein the isolated B lymphocyte cell line includes at least one of naïve B lymphocyte, immature B lymphocyte, transitional B lymphocyte, mature B lymphocyte, follicular B lymphocyte, memory B lymphocyte, plasmablast, or plasma cell.

### Claim at position 11

-18. (canceled)

### Claim 19 (depends on 1)

The isolated cell line of claim 1, wherein the membrane immunoglobulin includes at least one of a membrane anchor, an cytoplasmic domain, and an extracellular ligand-binding domain.

### Claim 20 (depends on 1)

The isolated cell line of claim 1, wherein the B lymphocyte cell line bears at least one chimeric B cell receptor capable of transducing signals for inducing expression of cytotoxic effector molecules.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The isolated cell line of claim 20, wherein the cytotoxic effector molecules include at least one of perforin, granzyme B, Fas ligand, or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

### Claim 23

An isolated recombinant cell line comprising:
an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin or recombinant B cell receptor that is reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding secreted immunoglobulin reactive to a second antigen;
wherein the isolated B lymphocyte cell line is capable of expressing cytotoxicity for at least one target cell.

### Claim 24 (depends on 23)

The isolated cell line of claim 23 further including:
the isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated nucleic acid encoding membrane immunoglobulin reactive to the second antigen.

### Claim 25 (depends on 23)

The isolated cell line of claim 23 further including:
the isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated nucleic acid encoding a secreted immunoglobulin reactive to a third antigen.

### Claim 26 (depends on 25)

The isolated cell line of claim 25, wherein the second antigen and the third antigen are different epitopes of a single antigenic polypeptide.

### Claim at position 20

-46. (canceled)

### Claim 47

A method for treating a disease in a vertebrate subject with an immunotherapeutic product comprising:
isolating from a vertebrate subject exposed to at least one second antigen, a B lymphocyte cell line expressing at least one endogenous secreted immunoglobulin reactive to the at least one second antigen;
introducing into the isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin or recombinant B cell receptor that is reactive to at least one first antigen to produce a recombinant B lymphocyte cell line;
introducing into the isolated B lymphocyte cell line at least one exogenous membrane receptor eliciting at least one effector molecule to produce a recombinant B lymphocyte cell line; and
selecting the recombinant B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen, expressing the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen for administration to one or more vertebrate subjects, and expressing the at least one exogenous recombinant B cell receptor eliciting at least one effector molecule.

### Claim 48 (depends on 47)

The method of claim 47 further including
administering the at least one first antigen to stimulate the recombinant B lymphocyte cell line; and
testing for the presence of the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen in the recombinant B lymphocyte cell line.

### Claim 49 (depends on 47)

The method of claim 47 further including:
administering to the vertebrate subject a pharmaceutical composition including the isolated B lymphocyte cell line; and
administering to the vertebrate subject the at least one first antigen to stimulate the isolated B lymphocyte cell line to produce the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen.

### Claim 50 (depends on 49)

The method of claim 49 further including
confirming the presence of the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen in a bloodstream of the vertebrate subject.

### Claim 51 (depends on 47)

The method of claim 47 further including
administering the at least one first antigen to stimulate the recombinant B lymphocyte cell line;
testing for the presence of the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen; and
administering to the vertebrate subject a pharmaceutical composition including the stimulated recombinant B lymphocyte cell line.

### Claim 52 (depends on 47)

The method of claim 47, wherein the recombinant B lymphocyte cell line is autologous to one of the one or more vertebrate subjects.

### Claim 53 (depends on 47)

The method of claim 47, wherein the recombinant B lymphocyte cell line is allogeneic to the one or more vertebrate subjects.

### Claim at position 28

-55. (canceled)

### Claim 56 (depends on 53)

The method of claim 53, wherein assessing cytotoxicity effects includes assessing at least one of perforin, granzyme B, Fas Ligand, or TRAIL.

### Claim at position 30

-61. (canceled)

### Claim 62

A method for treating a disease in a vertebrate subject with an immunotherapeutic product comprising:
introducing into at least one isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce at least one first isolated B lymphocyte cell line;
selecting the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen;
introducing into the at least one first isolated B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one second antigen to produce at least one isolated recombinant B lymphocyte cell line;
selecting the at least one isolated recombinant B lymphocyte cell line expressing the secreted one or more immunoglobulin reactive to the at least one second antigens for administration to one or more vertebrate subjects
introducing into the isolated B lymphocyte cell line at least one exogenous recombinant B cell receptor eliciting at least one effector molecule; and
selecting the at least one isolated recombinant B lymphocyte cell line expressing the one or more recombinant B cell receptors eliciting at least one cytotoxic effector molecule.

### Claim 63

(canceled)

### Claim 64 (depends on 62)

The method of claim 62, further including
administering the at least one first antigen to stimulate the at least one isolated recombinant B lymphocyte cell line; and
testing for the presence of the one or more secreted immunoglobulin reactive to the at least one second antigen in the at least one isolated recombinant B lymphocyte cell line.

### Claim 65 (depends on 62)

The method of claim 62, further including
administering to the vertebrate subject a pharmaceutical composition including the at least one isolated recombinant B lymphocyte cell line; and
administering to the vertebrate subject the at least one first antigen to stimulate the at least one isolated recombinant B lymphocyte cell line to produce the one or more exogenous secreted immunoglobulin reactive to the at least one second antigen.

### Claim 66 (depends on 65)

The method of claim 65, further including
confirming the presence of the at least one exogenous secreted immunoglobulin reactive to the at least one second antigen in a bloodstream of the vertebrate subject.

### Claim 67 (depends on 62)

The method of claim 62, further including
administering the at least one first antigen to stimulate the at least one isolated recombinant B lymphocyte cell line to produce the one or more exogenous secreted immunoglobulin reactive to the at least one second antigen; and
administering to the vertebrate subject a pharmaceutical composition including the stimulated at least one isolated recombinant B lymphocyte cell line.

### Claim 68 (depends on 62)

The method of claim 62, further including
introducing into the at least one first isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to the at least one second antigen.

### Claim 69 (depends on 62)

The method of claim 62, further including
introducing into the at least one isolated recombinant B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one third antigen to produce at least one isolated second recombinant B lymphocyte cell line; and
selecting the at least one isolated second recombinant B lymphocyte cell line expressing at least one of the secreted immunoglobulin reactive to the at least one second antigen and the secreted immunoglobulin reactive to the at least one third antigen.

### Claim at position 39

-72. (canceled)

### Claim 73 (depends on 65)

The method of claim 65, wherein the recombinant B lymphocyte cell line is autologous to one of the one or more vertebrate subjects.

### Claim 74 (depends on 65)

The method of claim 65, wherein the recombinant B lymphocyte cell line is allogeneic to the one or more vertebrate subjects.

### Claim at position 42

75-79. (canceled)
